Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

906
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
906
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

4.0K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

749
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
749
Cancer Survival Analysis01:21

Cancer Survival Analysis

863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombocytopenia in carriers and patients with antiphospholipid syndrome: insights from the nationwide START-APS registry.

Internal and emergency medicine·2026
Same author

Age-Related Platelet Cox-1 Upregulation in Atrial Fibrillation.

International journal of molecular sciences·2026
Same author

Pharmacological rhythm control strategy and outcomes in the oldest atrial fibrillation patients: an analysis of the nationwide Italian START registry.

Age and ageing·2026
Same author

No Time to Bleed! Ultrasound-Guided Management of a Pleural Biopsy Complication: A Case Report.

Respirology case reports·2026
Same author

Role of Mediterranean Diet Adherence on Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease Patients.

Biomolecules·2026
Same author

Correction to: Anticoagulation in chronic thromboembolic pulmonary hypertension: an updated systematic review and meta-analysis.

Internal and emergency medicine·2026

Related Experiment Video

Updated: May 5, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

6.9K

Exploring the Association Between Pulmonary Hypertension and Cancer: A Systematic Review and Meta-Analysis.

Filippo Catalani1, Arianna Pannunzio2, Emanuele Valeriani2,3

  • 1Department of Internal Medicine, Regional Hospital of Bellinzona e Valli, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.

Biomedicines
|May 4, 2026
PubMed
Summary

Cancer and pulmonary hypertension (PH) are linked, increasing mortality risk, especially in chronic thromboembolic pulmonary hypertension (CTEPH). Early detection of both conditions is crucial for patient outcomes.

Keywords:
CTEPHMPNPHcancerchronic thromboembolic pulmonary hypertensionmalignancymortalitymyeloproliferative neoplasmpulmonary circulationpulmonary hypertension

More Related Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

13.6K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

9.8K

Related Experiment Videos

Last Updated: May 5, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

6.9K
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

13.6K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

9.8K

Area of Science:

  • Cardiology
  • Oncology
  • Pulmonology

Background:

  • Pulmonary hypertension (PH) and cancer frequently coexist, with higher malignancy rates in PH patients, particularly those with chronic thromboembolic pulmonary hypertension (CTEPH).
  • Cancer and its treatments can induce PH through various mechanisms, highlighting a complex bidirectional relationship.

Purpose of the Study:

  • To systematically review and meta-analyze the prevalence of cancer in PH patients.
  • To evaluate mortality incidence and risk in PH patients with and without cancer, including specific analyses for CTEPH.
  • To assess the prevalence of PH and associated mortality risk in cancer patients.

Main Methods:

  • Systematic review and meta-analysis of 12 observational studies.
  • Inclusion of 4402 patients for quantitative analysis.
  • Evaluation of cancer prevalence, PH prevalence, and mortality data.

Main Results:

  • Overall cancer prevalence in PH patients was 13%.
  • Mortality incidence was significantly higher in PH patients with cancer (41%) compared to those without (10%).
  • In CTEPH patients, cancer was associated with a substantial increase in mortality incidence (19% vs. 4%). PH prevalence in cancer patients was 22%.

Conclusions:

  • A significant correlation exists between PH and cancer, adversely impacting mortality, particularly in CTEPH.
  • The findings underscore the need for vigilant clinical surveillance for early diagnosis of both cancer and PH in affected individuals.